查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2096878

慢性骨髓性白血病治療市場－2026-2032年全球市場預測

Chronic Myelogenous Leukemia Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，慢性骨髓性白血病治療市場規模將成長至 152.9 億美元，複合年成長率為 8.02%。

主要市場統計數據
基準年 2025 89億美元
預計年份：2026年 95.9億美元
預測年份 2032 152.9億美元
複合年成長率 (%) 8.02%

慢性骨髓性白血病)的治療重點在於抑制 BCR::ABL1 突變引起的疾病進展，從而提高長期存活率，減少治療副作用，並增加合格的患者達到無治療緩解的可能性。目前主流的治療方法是蛋白酪氨酸激酶慢性骨髓性白血病(TKI)，它已將 CML 的慢性期從曾經致命的惡性腫瘤轉變為許多患者可控的長期疾病，尤其是在及時進行診斷和分子反應監測的情況下。目前的臨床實踐強調基於國際標準的標準化定量 BCR::ABL1 轉錄本檢測、基於風險的治療選擇、抗藥性疾病中激酶結構域突變的評估，以及對心血管、代謝、肝臟、血液、胃腸道和呼吸系統安全性的謹慎管理。隨著患者長期接受治療，該行業的重點已從實現血液學和細胞遺傳學反應轉向最佳化主要分子和深度分子反應、藥物依從性、生活品質 (QOL)、減輕經濟負擔以及在治療失敗或耐受性差後基於證據的治療順序策略。

慢性骨髓性白血病治療格局的變革性變化

慢性骨髓性白血病 (CML) 的治療格局正從標準化的酪胺酸激酶抑制劑 (TKI) 療法轉向以精準醫學為基礎的以患者為中心的治療。如今，治療方案的選擇越來越注重考慮 BCR::ABL1 激酶結構域突變、基準風險評分、合併症情況、既往耐受性問題、藥物交互作用、妊娠計劃以及維持持續深度分子學緩解的患者在無治療狀態下達到緩解的可能性。第二代及更新的 TKI 為療效不佳或抗藥性的患者提供了更多選擇，而變構 BCR::ABL1 抑制劑則為某些先前接受過 TKI 治療的患者提供了作用機制不同的新療法。臨床指引日益強調早期獲得分子學緩解，如果轉錄本減少不足或因毒性導致用藥依從性降低，則應考慮調整治療方案。同時，多個國家非專利TKI 的普及正在重塑治療的可及性、保險報銷決策以及治療的長期經濟性。另一個顯著的變化是生存期的重要性日益凸顯。臨床醫生和保險公司在評估慢性骨髓性白血病的治療方案時，不僅考慮療效反應率，還考慮慢性毒性負擔、心血管風險管理、生育能力考慮、藥物依從性支持以及患者報告結果 (PRO)。

人工智慧在慢性骨髓性白血病治療的累積影響

人工智慧 (AI) 正開始在慢性骨髓性白血病)的治療領域產生影響，例如診斷支援、分子監測、臨床決策和研究。在臨床工作流程中，AI 驅動的分析可以輔助識別 BCR::ABL1 轉錄物隨時間變化的趨勢，並在受監管的系統中檢驗後，有助於識別療效不足、用藥依從性問題或突變檢測的必要性。在藥物研發領域，機器學習正被用於分析基因組、轉錄組、蛋白質組和真實世界臨床資料集，以識別抗藥性機制、改進生物標記策略、最佳化臨床試驗設計並改善患者分層。 AI 還具有增強藥物安全性監測的潛力，特別是針對與長期使用酪胺酸激酶抑制劑 (TKI) 相關的風險，例如血管、代謝、肝臟和胸膜/肺部事件，其方法是透過檢測電子不利事件記錄、登記系統和不良事件通報系統中的安全訊號。然而，其影響仍是累積的而非突破性的，因為其實施取決於資料品質、互通性、臨床相關性、可解釋性、隱私保護和監管。短期內，其最實際的價值在於提供決策支援工具，以輔助專家判斷、提高監測一致性並協助制定個人化的慢性骨髓性白血病（CML）治療方案。

關於慢性骨髓性白血病治療的關鍵區域見解

在北美，分子監測的普及率很高，多代酪氨酸激酶抑製劑（TKI）的獲取也十分廣泛，慢性粒細胞白血病（CML）治療的循證指南也得到了高度整合；然而，保險體系的設計、預先核准流程以及自付費用仍然影響著治療的依從性和持續性。在歐洲，集中化的血液學專家團隊、完善的報銷系統以及許多國家統一實施的標準化BCR::ABL1檢測都是優勢，歐洲的監管和藥物安全監測框架也支持對藥物進行系統性評估和長期安全性監測。亞太地區的情況極為複雜。日本、韓國、澳洲、中國和印度的都市區診斷和治療基礎設施完善，但在東南亞部分地區，分子檢測、專科血液學護理和晚期治療方案的可及性仍然存在差距。在拉丁美洲，透過公共採購、國家癌症計畫以及非專利TKI的供應增加，慢性骨髓性白血病治療的可及性正在改善；然而，診斷延遲、報銷體系的差異以及先進監測手段的普及程度不均仍然是重要的障礙。在中東，尤其是在高所得的海灣國家，慢性骨髓性白血病（CML）的治療正透過專業的癌症中心和政府主導的醫療保健投資不斷推進。然而，在受勞動力短缺和保險報銷體系碎片化影響的資源匱乏地區，醫療資源取得仍存在差距。非洲面臨最嚴峻的結構性限制，包括分子診斷的限制、經濟負擔、專科醫生密度低以及藥物取得管道分散等問題。永續的藥物取得計畫、檢查室能力建構和可靠的供應鏈對於改善CML的治療效果至關重要。

CML治療的關鍵群體分析

在東南亞國協，隨著癌症診斷能力的提高，對慢性骨髓性白血病）治療的需求日益成長，但高所得都市區醫療體系與資源匱乏地區在獲得標準化分子監測和晚期治療方面存在顯著差異。海灣合作理事會（GCC）國家的特點是公共醫療投入強勁、腫瘤基礎設施不斷完善，以及國際標準化治療方案的廣泛應用，這些都有助於患者在主要醫療中心獲得先進的CML治療，並透過集中式醫療體系改善治療的連續性。歐盟（EU）為癌症藥物監管、保險報銷評估、跨境安全監測和衛生技術評估提供了成熟的框架，從而能夠系統地引入CML治療，並重點關注成本效益、真實世界數據和長期治療效果。金磚國家（BRICS）擁有大規模且具有重要臨床意義的患者群體，中國、印度、巴西、俄羅斯和南非都在努力平衡本地生產、非專利酪胺酸激酶抑制劑（TKI）的供應、保險報銷體系改革和診斷基礎設施建設。七國集團（G7）國家普遍擁有先進的血液學網路、高水平的分子檢測能力以及廣泛的慢性粒細胞白血病（CML）已獲已通過核准治療方案，這使其在製定臨床指南、生成真實世界證據和監測長期安全性方面具有重要影響力。北約成員國的醫療衛生體系與北美和歐洲的高所得國家的醫療衛生體系高度重合，這些國家的醫療衛生體系具備強大的應急準備能力、供應鏈韌性和跨境監管合作，即使在公共衛生危機和地緣政治動盪時期，也能確保癌症治療的持續可及性。

各國慢性骨髓性白血病治療的關鍵見解

在美國，儘管慢性骨髓性白血病（CML）的治療選擇、先進的分子診斷和專科醫生主導的診療服務涵蓋範圍廣，但患者的經濟負擔、保險福利設計以及保險公司的核准流程仍可能影響治療的及時性。在加拿大，基於指引的血液病診療和公共醫療報銷體系相結合，但各省的就診時間和保險覆蓋範圍可能存在差異。在墨西哥，儘管癌症治療正在發展，但診斷檢測、專科醫生診療和藥物保險覆蓋方面的差異仍然影響著CML的治療。巴西擁有大規模的公共醫療體系和完善的腫瘤科服務，但地區差異會影響分子監測的及時性、轉診途徑和治療的連續性。在英國，結構化的臨床指南和集中化的醫療技術評估指導著CML治療的開展，並高度重視治療的價值、安全性和療效。德國、法國、義大利和西班牙擁有先進的血液疾病網路和廣泛的酪胺酸激酶抑制劑（TKI）應用，但報銷規則、區域管理結構和處方途徑各不相同。在俄羅斯，大型醫療中心擁有豐富的血液學專業知識，但由於基礎設施和採購系統的差異，都市區的醫療服務取得並不穩定。在中國，癌症診療基礎設施的快速發展、國內製藥能力的提升以及抗癌藥物醫保覆蓋範圍的擴大，正在增強大型醫院慢性粒細胞白血病（CML）治療的可及性，但農村地區的醫療服務獲取仍然不均衡。在印度，臨床需求旺盛，非專利抑制劑（TKI）學名藥的供應正在擴大，並且擁有強大的專科醫療中心，但經濟負擔、監測的一致性以及農村地區的醫療服務取得仍然是重大挑戰。在日本，CML的治療流程成熟，診斷標準高，並對長期治療進行嚴密的安全監測。在澳大利亞，國家醫保報銷系統和專科癌症診療網路提供了可靠的醫療服務獲取途徑，並支持基於指南的分子監測。在韓國，先進的診斷技術、數位醫療基礎設施和高標準的血液學診療相結合，為以精準醫療為重點的CML管理和持續追蹤提供了支持。

為慢性骨髓性白血病治療行業的領導者提供的實用建議

產業領導者應優先開發差異化的慢性骨髓性白血病)治療方案，以應對抗藥性、不耐受性、長期安全性以及實現無治療緩解等挑戰。研發策略應整合基於突變的患者選擇、可靠的分子反應終點、檢驗的停藥標準以及真實世界數據 (REW)，這些數據應涵蓋用藥依從性、毒性管理、合併症負擔和生活品質 (QOL) 等結果。銷售和醫療團隊應支援標準化的 BCR::ABL1 監測、針對臨床醫生開展關於反應里程碑的培訓、在治療失敗後及時進行突變檢測以及患者依從性計劃，以減少不必要的治療中斷。打入市場策略應透過在推出治療方案的同時建立檢測基礎設施、支持伴隨檢測、制定可靠的供應計劃以及提供針對當地醫療保健系統的報銷理由來解決區域診斷差異。此外，藥物組合規劃應評估TKI治療失敗後的定序治療潛力、變構抑制、聯合治療研究、兒童和妊娠相關護理考量，以及針對合併心血管和代謝疾病患者的合適治療方案。為增強信任，各機構應檢驗於透明的安全監測、公平的用藥途徑以及經臨床驗證、尊重隱私且旨在輔助而非取代血液科醫生決策的AI驅動型分析。

CML治療藥物分析的調查方法

針對慢性骨髓性白血病(CML) 治療的嚴謹調查方法需要結合二級文獻回顧、專家檢驗、監管評估和真實世界數據解讀。關鍵資訊來源包括同行評審的血液學期刊、臨床實踐指南、監管附加檔和安全資訊、臨床試驗註冊庫、藥物安全監測資料庫、公共保險報銷文件、癌症控制資料以及科學會議報告。分析應評估治療機制、治療方案定位、分子反應標準、BCR::ABL1 抗藥性突變、不利事件特徵、治療終止的證據、無治療緩解的要求以及監測標準。區域和國家層面的研究結果應根據醫療基礎設施指標、診斷可及性、報銷政策、公共採購條件以及腫瘤領域的准入條件進行檢驗。為確保資料完整性，所有研究結果應在多個可靠資訊來源中進行交叉引用，並應明確區分檢驗的臨床證據和方向性解讀。本調查方法旨在排除檢驗的商業性聲明，並評估基於證據的治療趨勢和策略意義，同時避免市場規模估算、佔有率分析和預測。

結論

慢性骨髓性白血病)的治療正朝著更精準、更安全、以患者為中心的方向發展。儘管酪胺酸激酶抑制劑 (TKI) 仍然是治療的基礎，但基於突變的定序、更深入的分子反應靶向、無治療緩解策略、長期毒性管理以及更便捷的標準化 BCR::ABL1 監測正在日益影響這一領域。區域差異仍然是一項嚴峻的挑戰，尤其是在分子診斷和血液疾病專科醫療服務資源有限的地區。人工智慧、真實世界數據和先進的藥物安全監測，在經過檢驗的數據、臨床管治和透明監督的支持下，可以增強決策能力。對於 CML 治療生態系統中的所有相關人員而言，最大的機會在於提高治療的永續性、減少副作用、擴大公平的治療機會、加強監測系統，以及將可衡量的臨床價值與創新相結合，造福慢性骨髓性白血病患者。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章慢性骨髓性白血病治療市場：依治療類型分類

  • 化療
    • Busulfan
    • 羥基脲
    • 干擾素α
  • 同時服用的藥物
  • 蛋白酪氨酸激酶抑制劑
    • 第一代
    • 第二代
      • Bosutinib
      • Dasatinib
      • 尼洛替尼
    • 第三代
      • Ponatinib
      • 阿西米尼
  • 單株抗體

第8章：慢性骨髓性白血病治療市場：依治療線分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第9章：慢性骨髓性白血病治療市場：依給藥途徑分類

  • 口服
  • 靜脈

第10章：慢性骨髓性白血病治療市場：依患者年齡層分類

  • 成年患者
  • 老年患者
  • 兒童患者

第11章慢性骨髓性白血病治療市場：依最終用戶分類

  • 診所
  • 居家醫療
  • 醫院
  • 專業醫療中心

第12章慢性骨髓性白血病治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章慢性骨髓性白血病治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章慢性骨髓性白血病治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章慢性骨髓性白血病治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Agios Pharmaceuticals, Inc.
  • Amgen Inc.
  • Amneal Pharmaceuticals, Inc.
  • Ascentage Pharma Group International Co., Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hansoh Pharmaceutical Group Co., Ltd.
  • Hikma Pharmaceuticals PLC
  • Ilyang Pharmaceutical Co., Ltd.
  • Innovent Biologics, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Rasna Therapeutics, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-957C47F953D7

The Chronic Myelogenous Leukemia Therapeutics Market is projected to grow by USD 15.29 billion at a CAGR of 8.02% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.90 billion
Estimated Year [2026] USD 9.59 billion
Forecast Year [2032] USD 15.29 billion
CAGR (%) 8.02%

Chronic myelogenous leukemia therapeutics are centered on controlling BCR::ABL1-driven disease progression, improving long-term survival, reducing treatment intolerance, and increasing the feasibility of treatment-free remission for eligible patients. The therapeutic landscape is anchored by tyrosine kinase inhibitors (TKIs), which have transformed chronic phase CML from a historically fatal malignancy into a manageable long-term condition for many patients, particularly when diagnosis and molecular response monitoring are timely. Current clinical practice emphasizes standardized quantitative BCR::ABL1 transcript testing on the International Scale, risk-adapted treatment selection, kinase domain mutation assessment in resistant disease, and careful management of cardiovascular, metabolic, hepatic, hematologic, gastrointestinal, and pulmonary safety considerations. As patients remain on therapy for extended periods, the industry focus has expanded from achieving hematologic and cytogenetic response to optimizing major and deep molecular response, adherence, quality of life, affordability, and evidence-based sequencing strategies after treatment failure or intolerance.

Transformative Shifts in the Chronic Myelogenous Leukemia Treatment Landscape

The CML therapeutics landscape is shifting from one-size-fits-all TKI therapy toward precision-guided, patient-centered care. Treatment selection increasingly considers BCR::ABL1 kinase domain mutations, baseline risk scores, comorbidity profiles, prior intolerance, drug-drug interactions, pregnancy planning, and the potential for treatment-free remission in patients with sustained deep molecular response. Second- and later-generation TKIs have broadened options for patients with inadequate response or resistance, while allosteric BCR::ABL1 inhibition has added a mechanistically distinct approach for selected patients after prior TKI exposure. Clinical guidelines increasingly prioritize early molecular response milestones, with treatment modification considered when transcript reduction is insufficient or toxicity compromises adherence. At the same time, the growing availability of generic TKIs in several countries is reshaping access, reimbursement decisions, and long-term treatment economics. Another major transformation is the rising importance of survivorship: clinicians and payers are assessing chronic myelogenous leukemia therapies not only by response rates but also by chronic toxicity burden, cardiovascular risk management, fertility considerations, adherence support, and patient-reported outcomes.

Cumulative Impact of Artificial Intelligence on CML Therapeutics

Artificial intelligence is beginning to influence chronic myelogenous leukemia therapeutics across diagnosis support, molecular monitoring, clinical decision-making, and research operations. In clinical workflows, AI-enabled analytics can support pattern recognition in longitudinal BCR::ABL1 transcript trends, helping flag suboptimal response, adherence issues, or the need for mutation testing when validated within regulated systems. In drug development, machine learning is used to analyze genomic, transcriptomic, proteomic, and real-world clinical datasets to identify resistance mechanisms, refine biomarker strategies, optimize trial design, and improve patient stratification. AI also has potential to strengthen pharmacovigilance by detecting safety signals from electronic health records, registries, and adverse event reporting systems, particularly for long-term TKI-associated risks such as vascular, metabolic, hepatic, and pleuropulmonary events. However, the impact remains cumulative rather than uniformly disruptive because adoption depends on data quality, interoperability, clinical validation, explainability, privacy protections, and regulatory oversight. The most practical near-term value lies in decision-support tools that complement specialist judgment, improve monitoring consistency, and help personalize sequencing of CML therapeutics.

Key Regional Insights Across CML Therapeutics

North America demonstrates high adoption of molecular monitoring, broad access to multiple TKI generations, and strong integration of evidence-based guidelines in CML care, although insurance design, prior authorization, and out-of-pocket costs continue to influence adherence and therapy continuity. Europe benefits from centralized hematology expertise, established reimbursement systems, and consistent use of standardized BCR::ABL1 testing across many countries, with European regulatory and pharmacovigilance frameworks supporting structured medicine evaluation and long-term safety surveillance. Asia-Pacific is highly diverse: Japan, South Korea, Australia, and urban centers in China and India have advanced diagnostic and treatment infrastructure, while parts of Southeast Asia still face uneven access to molecular testing, specialist hematology care, and later-line treatment options. Latin America is improving access to chronic myelogenous leukemia therapeutics through public procurement, national cancer programs, and greater availability of generic TKIs, but delays in diagnosis, reimbursement variability, and uneven availability of advanced monitoring remain important barriers. The Middle East is advancing CML care through specialized oncology centers and government-led healthcare investment, particularly in higher-income Gulf states, while access gaps persist in lower-resource settings affected by workforce limitations and fragmented reimbursement. Africa faces the most significant structural constraints, including limited molecular diagnostics, affordability challenges, lower specialist density, and fragmented medicine access, making sustainable access programs, laboratory capacity-building, and reliable supply chains essential for improved CML outcomes.

Key Group Insights for CML Therapeutics

ASEAN countries show rising demand for chronic myelogenous leukemia therapeutics as cancer diagnosis capacity improves, yet access to standardized molecular monitoring and later-line therapies varies substantially between higher-income urban systems and resource-constrained settings. The GCC is characterized by strong public healthcare investment, expanding oncology infrastructure, and growing use of internationally aligned treatment protocols, supporting access to advanced CML therapies in major centers and improved continuity of care through centralized health systems. The European Union provides a mature framework for oncology medicine regulation, reimbursement evaluation, cross-border safety surveillance, and health technology assessment, enabling structured adoption of CML therapeutics while emphasizing cost-effectiveness, real-world evidence, and long-term outcomes. BRICS countries represent a large and clinically important patient base, with China, India, Brazil, Russia, and South Africa each balancing local manufacturing, generic TKI availability, reimbursement reforms, and diagnostic infrastructure development. The G7 countries generally maintain advanced hematology networks, high levels of molecular testing, and broad availability of approved CML therapies, making them influential in clinical guideline development, real-world evidence generation, and long-term safety monitoring. NATO member states overlap significantly with high-income healthcare systems in North America and Europe, where preparedness, supply chain resilience, and cross-border regulatory cooperation can support continuity of oncology treatment access during public health or geopolitical disruption.

Key Country Insights for CML Therapeutics

The United States has extensive access to CML therapeutic options, advanced molecular diagnostics, and specialist-led care, although patient affordability, insurance benefit design, and payer authorization processes can affect timely treatment. Canada combines guideline-driven hematology care with public reimbursement mechanisms, while access timelines and formulary conditions can vary by province. Mexico is expanding oncology capacity, but disparities in diagnostic testing, specialist access, and medicine coverage continue to influence CML management. Brazil has a large public healthcare system with established oncology services, yet regional differences affect timely molecular monitoring, referral pathways, and therapy continuity. The United Kingdom uses structured clinical guidance and centralized health technology assessment to guide access to CML medicines, with strong emphasis on value, safety, and outcomes. Germany, France, Italy, and Spain maintain advanced hematology networks and broad access to TKIs, though reimbursement rules, regional administration, and prescribing pathways differ. Russia has significant hematology expertise in major centers, while access outside urban areas can be more variable due to infrastructure and procurement differences. China has rapidly expanded cancer care infrastructure, domestic pharmaceutical capacity, and reimbursement coverage for oncology medicines, strengthening CML treatment access in leading hospitals while rural access remains uneven. India has high clinical demand, expanding availability of generic TKIs, and strong specialist centers, but affordability, monitoring consistency, and rural access remain important challenges. Japan has mature CML care pathways, high diagnostic standards, and careful safety monitoring for long-term therapy. Australia provides strong access through national reimbursement systems and specialist oncology networks, supporting guideline-based molecular monitoring. South Korea combines advanced diagnostics, digital health infrastructure, and high-standard hematology care, supporting precision-oriented CML management and consistent follow-up.

Actionable Recommendations for CML Therapeutics Industry Leaders

Industry leaders should prioritize differentiated chronic myelogenous leukemia therapeutics that address resistance, intolerance, long-term safety, and treatment-free remission goals. Development strategies should integrate mutation-informed patient selection, robust molecular response endpoints, validated discontinuation criteria, and real-world evidence that captures adherence, toxicity management, comorbidity burden, and quality-of-life outcomes. Commercial and medical teams should support standardized BCR::ABL1 monitoring, clinician education on response milestones, timely mutation testing after treatment failure, and patient adherence programs that reduce avoidable treatment interruptions. Access strategies should account for regional diagnostic gaps by pairing therapeutic launches with laboratory capacity-building, companion testing support, reliable supply planning, and reimbursement evidence tailored to local health systems. Portfolio planning should also evaluate opportunities in sequencing after TKI failure, allosteric inhibition, combination research, pediatric and pregnancy-related care considerations, and therapies suitable for patients with cardiovascular or metabolic comorbidities. To strengthen trust, organizations should invest in transparent safety surveillance, equitable access initiatives, and AI-enabled analytics that are clinically validated, privacy-compliant, and designed to augment hematologist decision-making rather than replace it.

Research Methodology for CML Therapeutics Analysis

A rigorous research methodology for chronic myelogenous leukemia therapeutics should combine secondary evidence review, expert validation, regulatory assessment, and real-world data interpretation. Core sources include peer-reviewed hematology journals, clinical practice guidelines, regulatory labels and safety communications, clinical trial registries, pharmacovigilance databases, public reimbursement documents, cancer control resources, and scientific congress publications. The analysis should assess therapeutic mechanisms, line-of-therapy positioning, molecular response criteria, BCR::ABL1 resistance mutations, adverse event profiles, treatment discontinuation evidence, treatment-free remission requirements, and monitoring standards. Regional and country-level insights should be validated against healthcare infrastructure indicators, diagnostic availability, reimbursement policies, public procurement conditions, and oncology access conditions. To maintain data integrity, all findings should be cross-checked across multiple credible sources, with clear separation between verified clinical evidence and directional interpretation. The methodology should exclude unverified commercial claims and avoid market sizing, share analysis, and forecasting where the objective is to evaluate evidence-based therapeutic trends and strategic implications.

Conclusion

Chronic myelogenous leukemia therapeutics continue to evolve toward more precise, safer, and more patient-centered care. TKIs remain the foundation of treatment, but the field is increasingly shaped by mutation-guided sequencing, deeper molecular response goals, treatment-free remission strategies, long-term toxicity management, and improved access to standardized BCR::ABL1 monitoring. Regional disparities remain a defining challenge, particularly where molecular diagnostics and specialist hematology services are limited. Artificial intelligence, real-world evidence, and advanced pharmacovigilance can enhance decision-making if supported by validated data, clinical governance, and transparent oversight. For stakeholders across the CML therapeutics ecosystem, the strongest opportunities lie in improving treatment durability, reducing intolerance, expanding equitable access, strengthening monitoring infrastructure, and aligning innovation with measurable clinical value for patients living with chronic myelogenous leukemia.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Chronic Myelogenous Leukemia Therapeutics Market, by Therapy Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
    • 7.2.1. Busulfan
    • 7.2.2. Hydroxyurea
    • 7.2.3. Interferon Alfa
  • 7.3. Combination Agents
  • 7.4. Tyrosine Kinase Inhibitors
    • 7.4.1. First Generation
    • 7.4.2. Second Generation
      • 7.4.2.1. Bosutinib
      • 7.4.2.2. Dasatinib
      • 7.4.2.3. Nilotinib
    • 7.4.3. Third Generation
      • 7.4.3.1. Ponatinib
      • 7.4.3.2. Asciminib
  • 7.5. Monoclonal Antibodies

8. Chronic Myelogenous Leukemia Therapeutics Market, by Treatment Line

  • 8.1. Introduction
  • 8.2. First Line
  • 8.3. Second Line
  • 8.4. Third Line & Beyond

9. Chronic Myelogenous Leukemia Therapeutics Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Oral
  • 9.3. Intravenous

10. Chronic Myelogenous Leukemia Therapeutics Market, by Patient Age Group

  • 10.1. Introduction
  • 10.2. Adult Patients
  • 10.3. Geriatric Patients
  • 10.4. Pediatric Patients

11. Chronic Myelogenous Leukemia Therapeutics Market, by End User

  • 11.1. Introduction
  • 11.2. Clinics
  • 11.3. Home Care Settings
  • 11.4. Hospitals
  • 11.5. Specialty Centers

12. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Online Pharmacies
  • 12.4. Retail Pharmacies

13. Chronic Myelogenous Leukemia Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Chronic Myelogenous Leukemia Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chronic Myelogenous Leukemia Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Agios Pharmaceuticals, Inc.
  • 17.3. Amgen Inc.
  • 17.4. Amneal Pharmaceuticals, Inc.
  • 17.5. Ascentage Pharma Group International Co., Ltd.
  • 17.6. Astellas Pharma Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Aurobindo Pharma Limited
  • 17.9. Bayer AG
  • 17.10. Bristol-Myers Squibb Company
  • 17.11. Cipla Limited
  • 17.12. Dr. Reddy's Laboratories Ltd
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. GlaxoSmithKline plc
  • 17.15. Hansoh Pharmaceutical Group Co., Ltd.
  • 17.16. Hikma Pharmaceuticals PLC
  • 17.17. Ilyang Pharmaceutical Co., Ltd.
  • 17.18. Innovent Biologics, Inc.
  • 17.19. Johnson & Johnson Services, Inc.
  • 17.20. Lupin Limited
  • 17.21. Merck & Co., Inc.
  • 17.22. Novartis AG
  • 17.23. Otsuka Holdings Co., Ltd.
  • 17.24. Pfizer Inc.
  • 17.25. Rasna Therapeutics, Inc.
  • 17.26. Sanofi S.A.
  • 17.27. Sun Pharmaceutical Industries Limited
  • 17.28. Takeda Pharmaceutical Company Limited
  • 17.29. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHEMOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BUSULFAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BUSULFAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BUSULFAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HYDROXYUREA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYDROXYUREA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HYDROXYUREA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INTERFERON ALFA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INTERFERON ALFA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INTERFERON ALFA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMBINATION AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMBINATION AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMBINATION AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FIRST GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FIRST GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FIRST GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SECOND GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SECOND GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SECOND GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BOSUTINIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BOSUTINIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BOSUTINIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DASATINIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DASATINIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DASATINIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NILOTINIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NILOTINIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NILOTINIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THIRD GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THIRD GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THIRD GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PONATINIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PONATINIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PONATINIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASCIMINIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ASCIMINIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASCIMINIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIRST LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FIRST LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FIRST LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SECOND LINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SECOND LINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SECOND LINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THIRD LINE & BEYOND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 228. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. NATO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 251. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 252. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 254. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. CANADA CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 259. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 261. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 262. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 263. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 265. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. MEXICO CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 292. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 293. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 294. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 295. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2032 (USD MILLION)
  • TABLE 296. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 298. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. GERMANY CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 303. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 304. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY SECOND GENERATION, 2018-2032 (USD MILLION)
  • TABLE 305. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE, BY THIRD GENERATION, 2018-2032 (USD MILLION)
  • TABLE 306. FRANCE CHRONIC MYELOGENOUS LEUKEMIA THERAPEUTICS MARKET SIZE,